SGLT2 Inhibitors
-
healthReframing HFpEF as a Systemic Inflammatory Disorder
New models suggest heart failure with preserved ejection fraction is driven by a vicious inflammatory cycle involving the heart, liver, and pancreas, demanding an interdisciplinary treatment approach.
-
healthDiabetes Drug Dapagliflozin Slashes Heart Failure Risk in Genetic Carriers
Harvard, MIT, and Mass General Brigham researchers reveal dapagliflozin dramatically reduces heart failure hospitalizations in patients with inherited cardiomyopathy variants, marking a major step in precision preventive cardiology.
-
healthSGLT2 Inhibitors Cut Heart Transplant Rejection Risk in Diabetics
Meta-analysis finds SGLT2 inhibitors reduce rejection in heart transplant patients with diabetes, though mortality and other outcomes unchanged.
-
healthImmune Cells Retain 'Memory' of Obesity for Years After Weight Loss
New research reveals immune cells carry a lasting 'memory' of obesity, potentially raising disease risk for up to a decade after weight loss.
-
healthNew Study Reveals Safer Diabetes Drugs for Seniors
Real-world data identifies safer antihyperglycemic agents for older adults with type 2 diabetes, reducing risks of hypoglycemia and other serious complications.
-
healthNephrology Expert Patrick Mark on the Rising Threat of Kidney Disease
Professor Patrick Mark discusses the complex link between kidney disease and cardiovascular health, new treatment frontiers, and the critical need for proactive policy.